The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss before noncontrolling interest | -42,621 | -40,852 | -35,843 | -74,917 |
| Depreciation and amortization | 1,658 | 1,837 | 1,673 | 3,065 |
| Equity-based compensation | 4,945 | 5,703 | 6,676 | 12,957 |
| Gain on marketable securities, net | 413 | 743 | 732 | 1,942 |
| Gain on lease disposition | - | 172 | 0 | -143 |
| Impairment charges | - | 0 | 318 | - |
| Loss on disposal of equipment | 0 | -957 | -10 | -464 |
| Interest receivable | -95 | -110 | -538 | -672 |
| Prepaid and other assets | -609 | 1,559 | -593 | -7,202 |
| Accounts payable and accrued expenses | -5,957 | 2,156 | 51 | -8,126 |
| Income taxes payable | 0 | 50 | 120 | -526 |
| Net cash flows used in operating activities | -41,684 | -32,513 | -26,596 | -61,008 |
| Proceeds from sale of facility | - | 18,215 | - | - |
| Purchases of marketable securities | 44,754 | 40,400 | 78,538 | 98,138 |
| Sales and maturities of marketable securities | 83,366 | 56,030 | 112,753 | 149,239 |
| Purchase of equipment and facility expansion | 3,785 | 5,752 | 5,197 | 4,247 |
| Net cash flows provided by investing activities | 34,827 | 28,093 | 29,018 | 46,854 |
| Proceeds from sales of class a ordinary shares, net of offering costs | 7 | 17,145 | 7,102 | 0 |
| Payments on finance leases | 3 | 5 | -5 | 26 |
| Exercise of stock options | 211 | 494 | 854 | - |
| Repurchase of class a common stock amount | - | 0 | - | - |
| Net cash flows (used in) provided by financing activities | 215 | 17,634 | 7,961 | -26 |
| Net change in cash and cash equivalents | -6,642 | 13,214 | 10,383 | -14,180 |
| Cash, beginning of period | 108,537 | 95,323 | 99,120 | - |
| Cash, end of period | 101,895 | 108,537 | 95,323 | - |
PROKIDNEY CORP. (PROK)
PROKIDNEY CORP. (PROK)